Lupin inches up on receiving USFDA's approval for Amifampridine Tablets
Lupin is currently trading at Rs. 2000.55, up by 4.00 points or 0.20% from its previous closing of Rs. 1996.55 on the BSE.
The scrip opened at Rs. 2011.65 and has touched a high and low of Rs. 2014.95 and Rs. 1991.65 respectively. So far 9412 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2530.00 on 16-Jul-2026 and a 52 week low of Rs. 1893.25 on 23-Oct-2026.
Last one week high and low of the scrip stood at Rs. 2032.00 and Rs. 1935.00 respectively. The current market cap of the company is Rs. 91383.15 crore.
The promoters holding in the company stood at 46.84%, while Institutions and Non-Institutions held 47.06% and 6.09% respectively.
Lupin has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Applications (ANDA) for Amifampridine Tablets, 10 mg. Amifampridine Tablets, 10 mg, bioequivalent to the reference listed drug (RLD), Firdapse Tablets, 10 mg, of Catalyst Pharmaceuticals, Inc., for the indication in the approved labeling. The company is one of the first ANDA applicants and is eligible for 180 days of shared generic exclusivity.
.jpg)
